Table 3.

Considerations for use of auto-HCT and allo-HCT for indolent NHL

Auto-HCTAllo-HCT
Both of the following: All of the following: 
1. Chemosensitive disease 1. Ability to achieve low disease burden before transplant, may be following novel nonchemotherapy agents. 
2. Medically fit for high-dose therapy 2. Appropriate donor available 
AND one of the following: 3. Medically fit/”younger” age 
1. Relapse within 24 mo of initial chemoimmunotherapy AND one of the following: 
2. No more than third relapse 1. Not eligible or have received prior auto-HCT 
3. Desire for time off therapy 2. At least second relapse 
4. Short remission period after last therapy 3. Short remission period after last therapy 
Auto-HCTAllo-HCT
Both of the following: All of the following: 
1. Chemosensitive disease 1. Ability to achieve low disease burden before transplant, may be following novel nonchemotherapy agents. 
2. Medically fit for high-dose therapy 2. Appropriate donor available 
AND one of the following: 3. Medically fit/”younger” age 
1. Relapse within 24 mo of initial chemoimmunotherapy AND one of the following: 
2. No more than third relapse 1. Not eligible or have received prior auto-HCT 
3. Desire for time off therapy 2. At least second relapse 
4. Short remission period after last therapy 3. Short remission period after last therapy 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal